Abstract | OBJECTIVES: The aim of this retrospective study was to investigate the results of T-cell large granular lymphocytic leukemia treatment with fludarabine by assessing the complete hematologic response, the complete molecular response, progression-free survival, and overall survival. METHODS: RESULTS: Of the six patients investigated with T-cell large granular lymphocytic leukemia who were treated with fludarabine, five (83.3%) were female, and their median age was 36.5 years (range 18 to 73). The median lymphocyte level was 3.4 x 10(9)/L (0.5 to 8.9). All patients exhibited a monoclonal T-cell receptor gamma gene rearrangement at diagnosis. Two (33.3%) patients received fludarabine as first-line treatment, two (33.3%) for refractory disease, one (16.6%) for relapsed disease after the suspension of methotrexate treatment due to liver toxicity, and one (16.6%) due to dyspepsia. A complete hematologic response was achieved in all cases, and a complete molecular response was achieved in five out six cases (83.3%). During a mean follow-up period of 12 months, both the progression-free survival and overall survival rates were 100%. CONCLUSION:
|
Authors | Renata Oliveira Costa, Marcelo Bellesso, Dalton Alencar Fischer Chamone, Milton Artur Ruiz, Abrahão Elias Hallack Neto, Vera Lucia Aldred, Juliana Pereira |
Journal | Clinics (Sao Paulo, Brazil)
(Clinics (Sao Paulo))
Vol. 67
Issue 7
Pg. 745-8
(Jul 2012)
ISSN: 1980-5322 [Electronic] United States |
PMID | 22892917
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Vidarabine
- fludarabine
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Female
- Humans
- Leukemia, Large Granular Lymphocytic
(drug therapy, genetics)
- Male
- Middle Aged
- Retrospective Studies
- Survival Analysis
- Treatment Outcome
- Vidarabine
(analogs & derivatives, therapeutic use)
- Young Adult
|